As of 2024-12-14, the EV/EBITDA ratio of Homology Medicines Inc (FIXX) is 0.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FIXX's latest enterprise value is -6.57 mil USD. FIXX's TTM EBITDA according to its financial statements is -92.11 mil USD. Dividing these 2 quantities gives us the above FIXX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 16.2x | 14.8x |
| Forward P/E multiples | 14.5x - 17.4x | 15.2x |
| Fair Price | (970.75) - (1,091.10) | (1,011.56) |
| Upside | -4054.2% - -4544.4% | -4220.4% |
| Date | EV/EBITDA |
| 2024-11-22 | 0.07 |
| 2024-11-21 | 0.04 |
| 2024-11-20 | 0.03 |
| 2024-11-19 | 0.01 |
| 2024-11-18 | -0.03 |
| 2024-11-15 | -0.05 |
| 2024-11-14 | -0.09 |
| 2024-11-13 | -0.15 |
| 2024-11-12 | -0.21 |
| 2024-11-11 | -0.22 |
| 2024-11-08 | -0.23 |
| 2024-11-07 | -0.26 |
| 2024-11-06 | -0.27 |
| 2024-11-05 | -0.26 |
| 2024-11-04 | -0.25 |
| 2024-11-01 | -0.26 |
| 2024-10-31 | -0.26 |
| 2024-10-30 | -0.24 |
| 2024-10-29 | -0.26 |
| 2024-10-28 | -0.25 |
| 2024-10-25 | -0.31 |
| 2024-10-24 | -0.26 |
| 2024-10-23 | -0.26 |
| 2024-10-22 | -0.25 |
| 2024-10-21 | -0.28 |
| 2024-10-18 | -0.28 |
| 2024-10-17 | -0.29 |
| 2024-10-16 | -0.30 |
| 2024-10-15 | -0.27 |
| 2024-10-14 | -0.24 |
| 2024-10-11 | -0.28 |
| 2024-10-10 | -0.26 |
| 2024-10-09 | -0.26 |
| 2024-10-08 | -0.22 |
| 2024-10-07 | -0.20 |
| 2024-10-04 | -0.22 |
| 2024-10-03 | -0.19 |
| 2024-10-02 | -0.18 |
| 2024-10-01 | -0.16 |
| 2024-09-30 | -0.22 |
| 2024-09-27 | -0.24 |
| 2024-09-26 | -0.23 |
| 2024-09-25 | -0.22 |
| 2024-09-24 | -0.22 |
| 2024-09-23 | -0.21 |
| 2024-09-20 | -0.28 |
| 2024-09-19 | -0.26 |
| 2024-09-18 | -0.24 |
| 2024-09-17 | -0.27 |
| 2024-09-16 | -0.22 |